Plasmodium Immunotherapy for Lung Cancer

Inclusion Criteria

• •18-70 years of age, male or female
• •Unresectable stage III or IV non-small cell lung cancer, diagnosed by histological and radiological findings (UICC, Seventh Ed.), and of any histological subtype. Cancer staging during the initial diagnosis must be confirmed by radiographic findings (CT and/or MRI and/or PET-CT)
• •During study treatment, the patient should not receive other treatments, including chemotherapy, radiotherapy, targeted therapy, other biological therapy, physical therapy, traditional Chinese medicine, and so on
• •At least 5 half-life of the targeted drug (the half- life calculation is based on the targeted drug instructions) since the end the targeted therapy;More than 12 weeks since the end of radiotherapy or chemotherapy (common or continuous)
• •Expected survival \> 16 weeks
• •ECGO score of 0 or 1
• •PLT ≥100 × 10\^9/L, WBC ≥ 4 × 10\^9/L, and HGB ≥ 100 g/L; no significant morphological abnormalities of red blood cells, or anemia (iron deficiency anemia, autoimmune hemolytic anemia, thalassemia, etc.)
• •The patient's peripheral blood immune cell count and immune function test are close to normal or normal, and the heart and lungs and kidneys are normal.
• •The patient is willing to receive Plasmodium immunotherapy and is able to sign the informed consent
• •For female patients: the result of a pregnancy test must be negative at screening. All subjects must consent to use birth control methods during treatment and for two months after discharge
• •The subject is willing to follow the in-hospital exam and treatment and follow-up schedule
• •The patient can return for regular scheduled follow-up visits during the 2-year follow-up period
• •The subject agrees that the investigators may report and publish the results of this clinical study